Trials / Unknown
UnknownNCT03889808
Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Hospital Universitari de Bellvitge · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study to evaluate the seroprevalence of anti-bodies against C. difficile toxins A and B and the asymptomatic carriage of C. difficile in IBD patients according to the need and type of immunosuppressive therapy. The ultimate goal is to identify, among IBD patients, those with the highest risk of CDI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Determination of serum anti-toxin Abs for C. difficile |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2021-01-01
- Completion
- 2021-12-01
- First posted
- 2019-03-26
- Last updated
- 2019-04-02
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03889808. Inclusion in this directory is not an endorsement.